CYP11A1 Inhibitor Scaffolds Balancing Potency and Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is an urgent need for CYP11A1 inhibitors with good activity, high safety, and minimal side effects to treat steroid hormone-dependent cancers and other proliferative diseases, as existing compounds may have significant side effects and limited clinical development prospects.

Innovation Solution

Development of small molecule compounds, stereoisomers, tautomers, deuterated compounds, solvates, and co-crystals with selective inhibitory activity against CYP11A1, represented by specific structural formulas, targeting the cholesterol side-chain cleavage enzyme to block steroid biosynthesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing CYP11A1 inhibitor compounds are used, then some inhibitory activity is achieved, but significant side effects and limited clinical development prospects occur

Engineering Contradiction:

Improveinhibitory activityVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by systematically modifying molecular structure parameters including ring size (5-7 membered rings), heteroatom composition (N, O, S), substituent types (halogens, alkyl groups), and stereochemistry to optimize the balance between CYP11A1 inhibitory activity and reduction of side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality by introducing specific functional groups at particular positions on the molecular scaffold, such as placing electron-withdrawing groups at para positions or specific heteroatoms in ring structures, to enhance target selectivity and reduce off-target side effects while maintaining inhibitory activity

Inventive Principle:

Principle #3Local quality

2Productivity

If CYP11A1 inhibition is enhanced to treat hormone-refractory prostate cancer, then tumour growth suppression is improved, but safety and side effect profile may deteriorate

Engineering Contradiction:

Improvetumour growth suppressionVSAvoidsafety

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses steroid hormone synthesis pathway as an intermediary mechanism, where CYP11A1 inhibition blocks cholesterol conversion to pregnenolone, thereby suppressing downstream steroid hormone production that fuels cancer growth, achieving tumour suppression through this biochemical intermediary pathway

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs partial action by designing compounds with moderate to high inhibitory potency that selectively block CYP11A1 without completely abolishing all steroid synthesis, allowing sufficient hormone levels for normal physiological functions while suppressing cancer growth

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentEP4692079A1CYP11a1 inhibitor and use thereof

Publication Date: 2026.02.11 TIBET HAISCO PHARM CO LTD

AI summary

A compound as represented by formula (I), or a stereoisomer, tautomer, deuterated compound, solvate, co-crystal or pharmaceutically acceptable salt of the compound and a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating/preventing CYP11A1-mediated diseases, wherein each group in formula (I) is as defined in the description.